![]() ![]() Keywords: Adrenocortical carcinoma adrenal cancer systemic therapy mitotane More therapies continue to be explored and collaborative groups have formed around the world to work toward improved options for this patient population. Ablative techniques are often used for metastatic disease. Targeted systemic therapies have been less successful than this regimen. ![]() The EDP + mitotane regimen has a response rate of 23%. Once the disease becomes metastatic, the current treatment is palliative chemotherapy with etoposide, doxorubicin, and cisplatin (EDP) with mitotane. ![]() Adjuvant radiation to the tumor bed is suggested for patients with a high risk for recurrence. Adjuvant treatment with mitotane, the only approved medication for ACC, has been used since 1960. Therefore, many patients require systemic therapy. Seventy percent of patients present with stage III or IV disease. Survival at 5 years ranges from 82% for stage I disease to 13% for stage IV disease defined by distant metastases. However, local recurrence and metastatic disease are common. Surgery has been the mainstay of treatment and offers the best chance for a cure. Diagnosis occurs due to compressive symptoms from a large tumor, hormonal production, or incidental discovery on imaging studies. Policy of Dealing with Allegations of Research MisconductĪbstract: Adrenocortical carcinoma (ACC) is a rare and aggressive disease with an incidence of 1 per million people.Policy of Screening for Plagiarism Process. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |